Our finding is consistent with previous studies in hematological disease models of multiple myeloma (MYC-dependent) and acute myeloid leukemia, where it was demonstrated that BET inhibition produces a potent anti-proliferative effect [22, 24, 39]. This evidence concerns the gene MYC and AL amyloidosis.